Hunan Fangsheng Pharmaceutical Co.Ltd(603998) announced on March 6 that on March 4, 2022, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) held the fourth extraordinary meeting of the Fifth Board of directors in 2022, deliberated and approved the proposal on the company’s compliance with the conditions for non-public development and issuance of shares, the proposal on the company’s non-public offering plan in 2022 and other proposals related to the non-public offering of shares; Relevant proposals need to be submitted to the general meeting of shareholders for deliberation. This non-public offering of shares needs to be approved by the CSRC, and apply to the Shanghai Stock Exchange and registration and Clearing Company for stock issuance, registration and listing. The issuance object of this non-public offering is Xinyuan Industrial Investment controlled by Zhang Qinghua, the actual controller of the company, and the number of shares issued does not exceed about 56.96 million (including this number). The issue price is 4.74 yuan / share. This offering is intended to raise no more than 270 million yuan. After deducting the issuance expenses, it will be used to supplement working capital and repay bank loans.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) ‘s chairman and general manager are Zhang Qinghua, male, 48 years old, with college education background.
